| 22.05 22:14 | MÄRKTE USA/Etwas leichter - Fed weiter besorgt über hohe Inflation |
| 22.05 18:02 | MÄRKTE USA/Wall Street wenig bewegt vor Fed-Protokoll und Nvidia |
| 22.05 15:43 | MÄRKTE USA/Börsen treten auf der Stelle - Fed-Protokoll und Nvidia im Fokus |
| 22.05 14:11 | dpa-AFX: Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln |
| 22.05 14:01 | dpa-AFX: *BIOGEN EXPECTS TO CLOSE HUMAN IMMUNOLOGY BIOSCIENCES DEAL IN Q3 |
| 22.05 14:00 | dpa-AFX: *BIOGEN TO BUY HUMAN IMMUNOLOGY BIOSCIENCES FOR $1.15 BLN UPFRONT & UP TO $650MLN MILESTONE PAYMENTS |
| 22.05 13:30 | dpa-AFX: GNW-Adhoc: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences |
| 16.05 13:34 | dpa-AFX: *IONIS AND BIOGEN ANNOUNCE TOPLINE PHASE 1/2 STUDY RESULTS OF INVESTIGATIONAL DRUG IN AMYOTROPHIC LATERAL SCLEROSIS |
| 16.05 13:30 | dpa-AFX: GNW-Adhoc: Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis |
| 15.05 03:03 | dpa-AFX: Eisai Initiates Rolling BLA To FDA For LEQEMBI For Early Alzheimer's Disease Treatment |
| 26.04 03:36 | dpa-AFX: Biogen's Tofidence Gets Positive CHMP Opinion For Rheumatoid Arthritis,Juvenile Arthritis & COVID-19 |
| 25.04 22:05 | dpa-AFX: GNW-Adhoc: Biogen Receives Positive CHMP Opinion for TOFIDENCET (tocilizumab), a Biosimilar Referencing ROACTEMRA® |
| 25.04 09:49 | dpa-AFX: *DZ BANK SENKT FAIREN WERT FÜR BIOGEN AUF 214 (236) USD - 'HALTEN' |
| 25.04 09:49 | dpa-AFX: *DZ BANK CUTS FAIR VALUE FOR BIOGEN TO 214 (236) USD - 'HOLD' |
| 24.04 13:16 | dpa-AFX: Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook |
| 24.04 13:13 | dpa-AFX: *BIOGEN Q1 NET INCOME ATTRIBUTABLE TO BIOGEN $393.4 MLN VS $387.9 MLN LAST YEAR |
| 24.04 13:11 | dpa-AFX: *BIOGEN Q1 TOTAL REVENUE $2.29 BLN VS $2.463 BLN LAST YEAR |
| 24.04 13:11 | dpa-AFX: *BIOGEN CONTINUES TO EXPECT FY OPERATING INCOME TO GROW LOW-DOUBLE DIGIT PERCENTAGE |
| 24.04 13:10 | dpa-AFX: *BIOGEN CONTINUE TO EXPECT FY TOTAL REVENUE TO DECLINE BY A LOW- TO MID-SINGLE DIGIT PERCENTAGE |
| 24.04 13:10 | dpa-AFX: *BIOGEN REAFFIRMS 2024 FINANCIAL GUIDANCE: NON-GAAP EPS OF $15.00 TO $16.00 |
|
|
